Monitor upcoming IND filings for CBP (FHT-171) and EP300 degraders in 2027 and Phase 1 efficacy data for FHD-909 as key catalysts. Cash runway into H1 2028 reduces near-term dilution risk.
FHTX drugs
FHTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $4.20entry
- T+1 · 6mo ago +5.71%α +4.88% · $4.44
- T+5 · 6mo ago −0.71%α −2.22% · $4.17
- T+20 · 6mo ago −13.33%α −16.47% · $3.64
- T+60 · 4mo ago +9.76%α +5.93% · $4.61
Price Chart
How similar events traded
Executive Summary
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8M), and EPS of -$0.29 (vs consensus -$0.28, a slight miss). Cash stood at $183.6M, extended into H1 2028. Pipeline advances remain on track, with Phase 1 FHD-909 trial progressing and selective CBP/EP300 degraders approaching IND-enabling studies.
Key Financial Metrics
Key Facts
- Collaboration revenue $3.3M for Q1 2026, down from $6.0M YoY due to timing of work under Lilly agreement
- Net loss $19.9M vs $18.8M YoY; EPS -$0.29 vs -$0.30 YoY
- Cash, cash equivalents and marketable securities $183.6M as of March 31, 2026, providing runway into H1 2028
- FHD-909 Phase 1 dose-escalation trial on track; IND-enabling studies for CBP and EP300 degraders expected in 2026 with INDs in 2027
- Selected preclinical data presented at AACR 2026 showing combination activity with anti-PD-1 and KRAS inhibitors
Financial Impact
No material financial impact; company remains pre-revenue with collaboration revenue variability
Risk Factors
- Clinical trial delays or failures, particularly for FHD-909
- Dependence on Lilly collaboration for revenue and development
- Need for additional capital beyond 2028 runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031669 |
| Document: a2026mayfoghornirpresent.htm | 0001628280-26-031669 |
| Document: fhtx-20260507.htm | 0001628280-26-031669 |
| Document: 0001628280-26-031669-index-headers.html | 0001628280-26-031669 |
| Document: 0001628280-26-031669-index.html | 0001628280-26-031669 |
| Document: 0001628280-26-031669.txt | 0001628280-26-031669 |
| 8-K Data (Synthetic) | 0001628280-26-031669 |
Track record
9 reports on FHTX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $2.04 Now $1.79 −12.25% settles Dec 8
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
- Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
- Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
- May 7, 202627w ago 8-K Neutral 3/10 Viewing Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
- Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
- Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers